Blackrock, INC Schedule 13G passive stakes
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Entravision Communications Corporation's Class A Stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 9.0% Stake in Exelon Corporation
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.0% beneficial ownership stake in Exelon Corporation's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 7 to Schedule 13G, reporting a 6.9% beneficial ownership stake in Fate Therapeutics Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Passive Stake in Flowserve Corporation to 8.6%
BlackRock, Inc. has filed an Amendment No. 13 to its Schedule 13G, reporting a passive beneficial ownership of 8.6% of Flowserve Corporation's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.9% beneficial ownership stake in Forum Energy Technologies Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, disclosing its continued passive beneficial ownership of 9.3% of HP Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.4% passive beneficial ownership stake in Herc Holdings Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.2% passive beneficial ownership stake in Investar Holding Corp. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to its Schedule 13G, reporting a 9.6% beneficial ownership stake in Iridium Communications Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 8.2% of Axon Enterprise Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to its Schedule 13G, reporting a 7.1% beneficial ownership stake in Bandwidth Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 9.9% beneficial ownership stake in BlueLinx Holdings Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Boosts Stake in Blueprint Medicines Corp to 8.0%
BlackRock, Inc. has disclosed an increased passive ownership stake of 8.0% in Blueprint Medicines Corp, holding over 5 million shares as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 6.7% beneficial ownership stake in Business First Bancshares, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G: BlackRock Discloses 5.8% Stake in Cardiff Oncology, Inc.
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.8% beneficial ownership stake in Cardiff Oncology, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a beneficial ownership of 8.2% of Castle Biosciences Inc.'s common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reaffirming its beneficial ownership of 12.8% of Clearwater Paper Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.9% passive beneficial ownership stake in CommScope Holding Company, Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.8% Passive Stake in ConnectOne Bancorp
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% passive beneficial ownership stake in ConnectOne Bancorp Inc. as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.2% Passive Stake in Flex LTD Common Stock
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 7.2% of Flex LTD's common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant Passive Stake in Amicus Therapeutics, Disclosing 7.4% Ownership
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, reaffirming its passive beneficial ownership of 7.4% of Amicus Therapeutics Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Maintains Significant 7.8% Stake in Arcturus Therapeutics, Files Updated Ownership Disclosure
BlackRock, Inc. has filed an Amendment No. 5 to Schedule 13G, confirming its beneficial ownership of 7.8% of Arcturus Therapeutics Holdings Inc. common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 10 to its Schedule 13G, disclosing a 4.9% beneficial ownership stake in Ares Management Corporation as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Amends Stake in Arrowhead Pharmaceuticals, Disclosing 13.8% Beneficial Ownership
BlackRock, Inc. has filed an Amendment No. 3 to Schedule 13G, reporting a 13.8% beneficial ownership stake in Arrowhead Pharmaceuticals Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed a Schedule 13G, reporting a 5.1% beneficial ownership stake in Artiva Biotherapeutics, Inc. as of March 31, 2025, held in the ordinary course of business.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting an 8.0% beneficial ownership stake in Assurant, Inc.'s common stock as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.1% Passive Stake in Atea Pharmaceuticals
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Atea Pharmaceuticals, Inc. as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.95% beneficial ownership stake in Atlantic Union Bankshares Corp as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, revealing a beneficial ownership of 15.9% of Avista Corp's common stock as of March 31, 2025.
NYSE
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 6.7% of Credo Technology Group Holding Ltd's common stock as of March 31, 2025.